A study of Japanese patients with ulcerative colitis who were naïve to anti–tumor necrosis factor treatment found that patients preferred adalimumab to infliximab, but the researchers also reported no differences in the efficacy of the 2 treatments.
A study of Japanese patients with ulcerative colitis (UC) who were naïve to anti—tumor necrosis factor (TNF) treatment found that patients preferred adalimumab to infliximab, but the researchers also reported no differences in the efficacy of the 2 treatments. The study was conducted by Tsutomu Mizoshita, MD, PhD, and colleagues, and was published in Medicine (Baltimore) in August 2017.
During regular outpatient visits or during hospital stays, 25 patients with UC who were naïve to anti-TNF therapy were asked to evaluate, via questionnaire, whether they preferred to receive infliximab or adalimumab, and to provide reasons that contributed to their choice of therapy.
The researchers used the Mayo score and endoscopic activity index (EAI) as a measure of disease activity in the patients, before they initiated the treatment of their preference and at weeks 14 and 54. The primary difference between the 2 treatments is the mode (intravenous versus subcutaneous) and interval (every 2 months versus every 2 weeks) of administration. There is no difference in cost to the patient between infliximab and adalimumab in Japan, as healthcare is publicly funded.
Of the 25 patients who answered the questionnaire, 40% (n = 10) preferred infliximab, while 60% (n = 15) preferred adalimumab.
Patients who favored infliximab considered the following factors:
Patients who favored adalimumab considered the following factors:
There were no statistical differences in remission induction and maintenance between the infliximab and adalimumab groups with regard to response, remission, mucosal healing, steroid-free, or steroid-free remission rates at weeks 14 and 54. The efficacy of adalimumab in remission induction and maintenance was equivalent to that of infliximab in patients with UC who were naïve to anti-TNF therapy in this prospective study, but more patients preferred adalimumab.
The researchers believe their study is the first to show that there were no differences between infliximab and adalimumab with regard to response, remission, mucosal healing, steroid-free, and steroid-free remission rates in Japanese patients with UC who were naïve to anti-TNF therapy. It is also the first head-to-head comparison trial of the efficacy of remission induction and maintenance between infliximab and adalimumab in this population. The investigators suggest that further studies be conducted in larger populations to clarify which anti-TNF therapy is preferred by patients with UC.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Eye on Pharma: Interchangeability Labels and Expanded Biosimilar Partnerships
May 29th 2025The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple sclerosis, while 2 other companies expand their biosimilar partnership to include more products.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.